RecruitingAlzheimer Disease
Epidemiology and Biomarker Study in Alzheimer's Disease
Eligible age
55–75 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
Sponsor: Eli Lilly and Company
You may qualify if…
- ✓ The participant must self-report unimpaired cognition.
- ✓ The participant must have adequate literacy, vision, and hearing for neuropsychological assessments at the time of screening.
You may not qualify if…
- ✕ Have seen a doctor about memory concerns.
- ✕ Have a history or diagnosis of cognitive impairment, or significant other neurodegenerative disease that can affect cognition.
- ✕ Are currently enrolled or have previously participated in any Alzheimer's Disease (AD)-related study involving an investigational drug intervention.
- ✕ Are currently using or have previously used prescription medications for treatment of mild cognitive impairment (MCI) or dementia such as amyloid targeting therapy (that is, lecanemab, donanemab, aducanumab), cholinesterase inhibitors (for example, benzgalantamine, donepezil, galantamine, rivastigmine), and memantine.
Where it's recruiting
Texas
Houston
Source: ClinicalTrials.gov · NCT07142954 · last updated 2026-05-14